葡萄糖受体对手的额外螺旋结合部位
Ali Jazayeri1, Andrew S Doré1, Daniel Lamb1
1Heptares Therapeutics Ltd, BioPark, Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AX, UK.
Nature
|April 26, 2016
概括
研究人员使用X射线结晶学阐明了葡萄糖受体 (GCGR) 的新结合位. 这一发现为针对2型糖尿病的基于结构的药物设计提供了新的途径.
科学领域:
- 结构生物学
- 药理学
- 内分泌学
背景情况:
- 葡萄糖对葡萄糖稳定至关重要,通过葡萄糖受体 (GCGR) 起作用.
- 在2型糖尿病治疗中,GCGR抗体具有前景.
- 之前的GCGR结构缺乏解决的连接位.
研究的目的:
- 确定与抗体结合的人类GCGR的高分辨率结构.
- 识别结合位并了解对抗的机制.
- 为设计新的GCGR向药物提供结构基础.
主要方法:
- 人类GCGR的X射线晶体学复合MK-0893在2.5 Å的分辨率.
- 针对位点的突变发生,以验证参与抗体结合的关键残留物.
主要成果:
- 抗剂MK-0893结合在TM6和TM7之间的7TM捆外的一个新位.
- 已确认的残留物在MK-0893结合中的作用.
- 通过限制TM6运动来预防葡萄糖诱导的受体激活.
结论:
- 对GCGR抗剂的新型结合部位已被确定.
- 这一发现提升了对B类G蛋白结合受体激活机制的理解.
- 该结构为基于结构的药物设计提供了基础,用于GCGR和相关受体.
更多相关视频
相关概念视频
Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Insulin: The Receptor and Signaling Pathways
5.8K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
5.8K
Oral Hypoglycemic Agents: Glinides
921
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
921
Hypoglycemia and Glucagon
1.3K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K
GPCRs Regulate Adenylyl Cylase Activity
8.2K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
8.2K
Spare Receptors
4.8K
Some receptors remain unoccupied even when an agonist produces a maximal response. Such empty ones are called spare receptors. In presence of spare receptors the maximum effect of an agonist drug is achieved with fewer than 100% of the receptors being occupied. To determine the presence of spare receptors, scientists often compare the concentration of the drug needed to produce 50% of the maximum effect (EC50) with the concentration of the drug needed to occupy 50% of the receptors (Kd). If the...
4.8K


